BioSpace News Archive

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California.

Agilent Technologies Inc. announced that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award.

Juno Pharmaceuticals Canada, a Canadian specialty pharmaceutical company, announced it has received approval from Health Canada to import ketamine solution for injection pursuant to Health Canada’s exceptional importation and sale guidelines.

IMUNON, Inc. announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023.

Evoke, an Inizio company and leading global health brand, experience, and communications platform, announced the appointment of Cheryl Fielding as Chief Client Officer.

AmerisourceBergen, a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.

Capricor Therapeutics will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023.

GT Biopharma, Inc. has named Charles J. Casamento to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board, the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board as of May 1, 2023.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023.

Veracyte, Inc. (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive tumor behavior.